---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-243475"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2024-10-25T23:59:59+00:00"
generated_at: "2026-05-30T10:08:08.474812+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences reports interim TYRA-300 data: 54.5% confirmed PR in FGFR3+ mUC at ≥90 mg QD

## Summary
- As of Aug 15, 2024, 41 patients enrolled in SURF301 Phase 1; 6/11 (54.5%) FGFR3+ mUC patients at ≥90 mg QD achieved confirmed partial response, 3 ongoing.
- 100% disease control rate (PR + stable disease) observed in patients at ≥90 mg QD.
- TYRA-300 generally well-tolerated; no Gr4+ TRAEs, 1 DLT (Gr3 diarrhea) and 1 discontinuation (Gr3 ALT) at 90 mg QD.
- Director Siddarth Subramony resigned from Board and Compensation Committee effective Oct 24, 2024, not due to any disagreement.

## SEC filing metadata
- accession: 0001193125-24-243475
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2024-10-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000119312524243475/0001193125-24-243475-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000119312524243475/d898462d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-243475
- JSON: https://secwatch.observer/filing/0001193125-24-243475.json
- Plain text: https://secwatch.observer/filing/0001193125-24-243475.txt

## Key facts
- Executive change
  Siddarth Subramony resigned as Director at Tyra Biosciences, Inc..
  - Action: resigned
  - Role: Director
  source text: On October 24, 2024, Siddarth Subramony, Ph.D. resigned from the Board of Directors (the Board) of Tyra Biosciences, Inc. (Tyra or the Company) and the Compensation Committee of the Board (the Compensation Committee) effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1863127/000119312524243475/0001193125-24-243475-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.